L3VLUP
ProSign in

INCY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INCYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INCY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterINCYLLY
Q3 202016 holders, $5.4bn33 holders, $14.1bn
Q4 202015 holders, $5.1bn29 holders, $17.3bn
Q1 202113 holders, $4.6bn24 holders, $23.0bn
Q2 202113 holders, $5.3bn24 holders, $27.8bn
Q3 202115 holders, $3.9bn31 holders, $29.9bn
Q4 202121 holders, $3.6bn31 holders, $34.7bn
Q1 202217 holders, $3.5bn24 holders, $35.3bn
Q2 202218 holders, $3.6bn33 holders, $42.7bn
Q3 202217 holders, $3.0bn31 holders, $43.4bn
Q4 202221 holders, $3.5bn31 holders, $46.6bn
Q1 202321 holders, $2.8bn33 holders, $44.3bn
Q2 202323 holders, $2.7bn37 holders, $59.6bn
Q3 202323 holders, $2.5bn44 holders, $67.6bn
Q4 202319 holders, $2.5bn45 holders, $73.6bn
Q1 202420 holders, $2.1bn41 holders, $95.3bn
Q2 202418 holders, $2.1bn43 holders, $110bn
Q3 202416 holders, $2.2bn45 holders, $107bn
Q4 202414 holders, $2.0bn46 holders, $93.9bn
Q1 202513 holders, $1.9bn42 holders, $98.4bn
Q2 202515 holders, $2.6bn43 holders, $93.2bn
Q3 202513 holders, $3.0bn39 holders, $86.7bn
Q4 202513 holders, $3.5bn41 holders, $123bn
Q1 202613 holders, $3.4bn39 holders, $106bn
Q2 202615 holders, $4.4bn44 holders, $132bn
INCY

Incyte Corp

Holders
19
Reported value
$2.5bn
Buyers
8
Sellers
9

Breadth -1 among 93 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INCY (5)

ARK Investment Management LLC, Caxton Associates LLP, PDT Partners LLC, Schonfeld Strategic Advisors LLC, Voloridge Investment Management LLC

Only LLY (31)

AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Citadel Advisors LLC, Coatue Management LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Soros Fund Management LLC, Susquehanna International Group LLP, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →